Demonstrating Feasibility of a Novel Diagnostic for Thrombosis Risk

This project will demonstrate the feasibility of applying a sophisticated analysis method for the detection of clinically relevant blood clotting defects in patients to an emerging diagnostic sensor platform technology that can be applied to improve outcomes in many high mortality conditions, particularly common amongst the ageing population. Thrombotic disorders are top causes for death, either as disease states – myocardial infarction or ischemic stroke, or as potential complications to most in-hospital treatments, including childbirth and routine surgery.
The project will focus on demonstrating clear health benefits and attractive business case through the application of novel diagnostic techniques and will be delivered by Highland Biosciences, a micro SME that leverages a strong network of collaborators proven to deliver successful TSB funded projects.